Applied Therapeutics, Inc. (APLT) quarterly income statement — complete revenue, gross profit & net income history
| Sales/Revenue | 1M | 0 | 0 | 0 | 122K | 144K | 190K | -667K | 0 | 0 | 10.66M | 0 |
| Revenue Growth % | 719.67% | -100% | -100% | 100% | - | - | -98.22% | - | - | - | - | - |
| Cost of Goods Sold | 0 | 9.92M | 7.84M | 11.7M | 0 | 122K | 12.22M | 15.3M | 118K | 11.88M | 0 | 55.63M |
| COGS % of Revenue | - | - | - | - | - | 84.72% | 6430% | -2294.3% | - | - | - | - |
| Gross Profit | 1M | -9.92M | -7.84M | -11.7M | 122K | 22K | -12.03M | -15.97M | -118K | -11.88M | 10.66M | -55.63M |
| Gross Margin % | 100% | - | - | - | 100% | 15.28% | -6330% | 2394.3% | - | - | 100% | - |
| Gross Profit Growth % | 719.67% | -45204.55% | 34.84% | 26.77% | 203.39% | 100.19% | -212.82% | 71.29% | - | - | - | - |
| Operating Expenses | 17.76M | 13.18M | 17.69M | 21.33M | 29.86M | 20.46M | 9.07M | 5.04M | 15.38M | 5.29M | 21.52M | -36.66M |
| OpEx % of Revenue | 1775.8% | - | - | - | 24479.51% | 14209.72% | 4771.58% | -755.32% | - | - | 201.86% | - |
| Selling, General & Admin | 9.37M | 13.18M | 17.69M | 21.33M | 15.04M | 10.58M | 9.07M | 5.04M | 4.71M | 5.29M | 5.58M | 6.88M |
| SG&A % of Revenue | 936.6% | - | - | - | 12325.41% | 7347.22% | 4771.58% | -755.32% | - | - | 52.37% | - |
| Research & Development | 9.6M | 9.92M | 7.84M | 11.7M | 14.83M | 10M | 12.22M | 15.3M | 10.79M | 11.88M | 15.94M | 12.09M |
| R&D % of Revenue | 960.1% | - | - | - | 12154.1% | 6947.22% | 6430% | -2294.3% | - | - | 149.48% | - |
| Other Operating Expenses | -1000K | -1000K | -1000K | -1000K | 0 | -122K | -1000K | -1000K | -118K | -1000K | 0 | -1000K |
| Operating Income | -16.76M | -23.1M | -25.52M | -33.02M | -29.74M | -20.44M | -21.09M | -21.01M | -15.49M | -17.18M | -10.86M | -18.97M |
| Operating Margin % | -1675.8% | - | - | - | -24379.51% | -14194.44% | -11101.58% | 3149.63% | - | - | -101.86% | - |
| Operating Income Growth % | 43.66% | -13% | -21.01% | -57.19% | -91.95% | -19% | -94.26% | -10.73% | 19.95% | 20.19% | 53% | 30.03% |
| EBITDA | -16.65M | -23.1M | -25.52M | -33.02M | -29.64M | -20.32M | -21.09M | -21M | -15.38M | -17.18M | -10.74M | -18.97M |
| EBITDA Margin % | -1664.7% | - | - | - | -24294.26% | -14109.72% | -11101.05% | 3148.73% | - | - | -100.79% | - |
| EBITDA Growth % | 43.83% | -13.68% | -21.02% | -57.23% | -92.75% | -18.3% | -96.31% | -10.71% | 20.1% | 19.78% | 53.27% | 30.03% |
| D&A (Non-Cash Add-back) | 111K | 500 | 250 | 0 | 104K | 122K | 1K | 6K | 118K | 500 | 114K | 1K |
| EBIT | -18.99M | -23.1M | -25.52M | -33.02M | -29.74M | -20.44M | -21.09M | -21.01M | -15.49M | -17.18M | -10.86M | -18.97M |
| Net Interest Income | 144K | 364K | 621K | 962K | 1.36M | 628K | 586K | 352K | 392K | 408K | 221K | 271K |
| Interest Income | 144K | 364K | 621K | 962K | 1.36M | 628K | 586K | 352K | 392K | 408K | 221K | 271K |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
| Other Income/Expense | -2.23M | 1.77M | 3.7M | 77.03M | -38.85M | 23.34M | -62.84M | -16.67M | -26.88M | -12.4M | 721K | 4.54M |
| Pretax Income | -18.99M | -21.33M | -21.82M | 44.01M | -68.59M | 2.9M | -83.94M | -37.68M | -42.37M | -29.58M | -10.14M | -14.43M |
| Pretax Margin % | -1899% | - | - | - | -56222.13% | 2012.5% | -44177.89% | 5649.03% | - | - | -95.09% | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -18.99M | -21.33M | -21.82M | 44.01M | -68.59M | 2.9M | -83.94M | -37.68M | -42.37M | -29.58M | -10.14M | -14.43M |
| Net Margin % | -1899% | - | - | - | -56222.13% | 2012.5% | -44177.89% | 5649.03% | - | - | -95.09% | - |
| Net Income Growth % | 72.31% | -836.02% | 74% | 216.79% | -61.89% | 109.8% | -728.04% | -161.13% | -121.82% | -14.39% | 56.16% | 46.87% |
| Net Income (Continuing) | -18.99M | -21.33M | -21.82M | 44.01M | -68.59M | 2.9M | -83.94M | -37.68M | -42.37M | -29.58M | -10.14M | -14.43M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.13 | -0.15 | -0.15 | 0.32 | -0.48 | -0.13 | -0.67 | -0.45 | -0.47 | -0.37 | -0.18 | -0.12 |
| EPS Growth % | 72.92% | -15.38% | 77.61% | 171.11% | -2.13% | 64.86% | -272.22% | -275% | -17.5% | 71.09% | 79.55% | 88.46% |
| EPS (Basic) | -0.13 | -0.15 | -0.15 | 0.32 | -0.48 | 0.02 | -0.67 | -0.45 | -0.47 | -0.37 | -0.18 | -0.12 |
| Diluted Shares Outstanding | 145.56M | 145.09M | 144.79M | 139.53M | 144.35M | 144.35M | 125.32M | 84.24M | 90.67M | 79.04M | 56.36M | 49.95M |
| Basic Shares Outstanding | 145.56M | 145.09M | 144.79M | 139.53M | 144.35M | 144.35M | 125.32M | 84.24M | 90.67M | 79.04M | 56.32M | 49.95M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - |